|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table 3. Baseline characteristics of sub-cohort of new metformin users** | | | | | | |
| **Characteristic** | | | **All participants (n=2,911,051)**  **Number (%)** | | **Metformin users (n=264,641)**  **Number (%)** | **Non-users of metformin (n=2,646,410)**  **Number (%)** |
|
| Age, mean years (SD) | | | 56.1 (±13.7) | | 56.1 (±13.7) | 56.1 (±13.7) |
| Sex |  | |  | |  |  |
|  | Men | | 1,712,315 (58.8) | | 155,665 (58.8) | 1,556,650 (58.8) |
|  | Women | | 1,198,736 (41.2) | | 108,976 (41.2) | 1,089,760 (41.2) |
| Residence in Sweden | | |  | |  |  |
|  | Eastern/Southern | | 2,332,627 (80.1) | | 208,846 (79.0) | 2,123,781 (80.3) |
|  | Northern | | 570,463 (19.6) | | 55,438 (21.0) | 515,025 (19.5) |
|  | Unknown | | 7,961 (0.3) | | 357 (0.1) | 7,604 (0.3) |
| Smoking a |  | | 67,660 (2.3) | | 7,924 (3.0) | 59,736 (2.3) |
| Alcohol overconsumption a | | | 72,507 (2.5) | | 7,490 (2.8) | 65,017 (2.5) |
| Use of NSAIDs or aspirin | | | 913,244 (31.4) | | 113,946 (43.1) | 799,298 (30.2) |
| Use of statins | | | 612,684 (21.1) | | 135,902 (51.4) | 476,782 (18.0) |
| Duration of follow-up, mean years (SD) | | | 4.4 (±2.7) | | 4.4 (±2.7) | 4.4 (±2.7) |
| ESCC cases | |  | | 636 (0.02) | 37 (0.01) | 599 (0.02) |
| ESCC Incidence per 100,000 person-years (95% CI) | | | 5.0 (4.6-5.4) | | 3.2 (2.3-4.4) | 5.2 (4.8-5.6) |
| Death during follow-up | | | 220,131 (7.6) | | 25,548 (9.7) | 194,583 (7.4) |
| a Assessed within the ten years before study entry | | | | | | |
| Abbreviations: ESCC=esophageal squamous cell carcinoma, NSAIDs= non-steroidal anti-inflammatory drugs, SD=standard deviation, CI=confidence interval | | | | | | |
|  | | | | | | |